Haloperidol decanoate

癸酸氟哌啶醇

Report date: 2022/09/08 17:54:37
NME

Base Information

Drug NameHaloperidol decanoate
Drug Alias Name氟哌啶醇癸酸Ha-loperidolidekanoaattiDecanoato de haloperidolHaloperidoli decanoasHaloperi-doldekanoat +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine D2 receptor antagonists
TargetsDopamine D2 receptor
Therapy Area/IndicationsSchizophreniaPsychotic DisordersAnxiety Disorders +[6] 
Global Approved IndicationsPsychotic DisordersAnxiety DisordersMental Disorders +[4] 
Approved Indications in ChinaPsychotic DisordersAnxiety DisordersAnxiety
Original Approved Country/TerritoryUnited States
Original Approved Date1986/01/14
Country/TerritoryUnited StatesTanzaniaMainland China +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative MedicineJohnson & Johnson
China Registration ClassN/A

Develop Information

Active CompaniesEssential Pharma LtdJohnson & Johnson Innovative MedicineClinigen Ltd +[4] 
Inactive CompaniesCase Western Reserve UniversityJanssen Pharmaceuticals Inc
Active IndicationsPsychotic DisordersAnxiety DisordersAnxiety
Inactive IndicationsSchizophreniaMental DisordersMedication Adherence

Other Information

ATC CodeN05AD01
Related LinksWikipediaDrugBankKEGG